The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane.
about
The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activityActivation of the epidermal growth factor (EGF) receptor induces formation of EGF receptor- and Grb2-containing clathrin-coated pitsSustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissueClathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartmentsRegulation of ErbB2 receptor status by the proteasomal DUB POH1.HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cellsQuantifying the effects of co-expressing EGFR and HER2 on HER activation and trafficking.Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation.Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.Endocytosis and intracellular trafficking of ErbBs.The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR.Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity.Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses.Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells.Cigarette Smoke Induces Human Epidermal Receptor 2-Dependent Changes in Epithelial Permeability.Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancerEpidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosisPertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with TrastuzumabMechanisms of ErbB receptor negative regulation and relevance in cancer.A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2.The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation.Septins: Regulators of Protein Stability.Endocytosis and signalling: a meeting with mathematics.Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cellsThe epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.The Mysterious Ways of ErbB2/HER2 TraffickingResolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach.MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.ErbB2 dephosphorylation and anti-proliferative effects of neuregulin-1 in ErbB2-overexpressing cells; re-evaluation of their low-affinity interaction.EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes.Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.Internalization and Recycling of the HER2 Receptor on Human Breast Adenocarcinoma Cells Treated with Targeted Phototoxic Protein DARPinminiSOG.A novel cross-talk between endothelin and ErbB receptors controlling glutamate transporter expression in astrocytes.Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane.Simulation of the regulation of EGFR endocytosis and EGFR-ERK signaling by endophilin-mediated RhoA-EGFR crosstalk.
P2860
Q24314999-B932F4DD-56E5-4F3E-9AE8-A23F68EC9134Q30159982-F6239E1B-F12A-4881-A24A-D811F97EC792Q30428519-40F2BAB6-AA78-48AF-A9E2-FD4300765D72Q30439237-3A58F9BC-D8DC-4A80-A421-5072B97628BFQ30479942-D9ECB5E4-9017-43B1-A01F-4EF1B7DE17BBQ31107044-3E7EFEF2-618D-47DD-BE5C-B9EDD45D1CDAQ33444766-54D7E4F3-2FBA-4B9D-8FA7-BB6CEBD1B73AQ33514127-7C96D757-8066-481F-A9E6-BB7EE0B0A49DQ33827628-AAC8A3F9-AED9-43D5-B364-7E4210D69AACQ34249179-841FDCCC-65C6-494B-ACB0-DE2671ED0F65Q34483533-5AAD23F2-CCA0-4695-BCB2-727408AD3F09Q34827744-61762C58-FA2E-40F5-BB24-AA9EC39AE285Q35491037-991E917F-4822-4759-97A3-565E2149F711Q36092368-BBB35E0C-CEA1-4DB5-8DCD-845C8157AE50Q36254464-68549D31-B88F-4D63-A35C-6077BF55E7DBQ36983366-D5D0F250-F56F-4F90-B07B-1180C83DE9E0Q37088300-91DCC59E-6B20-44AE-BFE6-939EE6C9595AQ37089778-1A001F70-10E4-408C-8EF9-ACD37DD81A3FQ37101643-22AA6DE2-47D2-4807-82FD-D1BA2BD4C917Q37148772-E960B335-2D29-499E-9F95-709D404FD119Q37244805-51F55C47-06BC-478E-8DD7-1D253F3CA500Q37251593-136B8326-7C26-47B1-9BF0-0C0840DFCFD8Q37400805-2924C8ED-5A54-4D3A-81D8-83F4FCA41F17Q37516409-03B98E17-0BF1-4F7C-850F-C41012175CB5Q37549617-9F5BBF86-A446-4039-9D3C-500FA968B2F1Q37698914-5DB5EA76-53BB-475A-B87D-EE0C34295B93Q38083086-EE32BAA8-52A8-4E0B-8DA3-86313C80483FQ38237727-54139F1A-F6FD-4540-83F6-64B74AA1AEB1Q38292832-561854EB-4A13-4486-8BB9-D57472180343Q38717175-03F6B685-E493-4255-9285-9A698DD2DE26Q39184409-9F56979D-EAA8-4DCE-8486-3E8C4CA0C799Q40156909-CDB22C39-170A-46F4-985C-0E2A2D1D5BAFQ41773399-13E0504F-FCFA-4DE0-8262-82B74843CB06Q42091935-8FD5F712-DCB7-4013-9438-9761ED45769CQ42507533-9BC835A9-E3E9-4E04-B474-977A65F31F1BQ46935318-53A8903A-AF23-4843-BB05-84DF624357DEQ51877889-3919C102-30BC-4532-9C86-5DADFA08606E
P2860
The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The inhibitory effect of ErbB2 ...... plexes at the plasma membrane.
@en
The inhibitory effect of ErbB2 ...... plexes at the plasma membrane.
@nl
type
label
The inhibitory effect of ErbB2 ...... plexes at the plasma membrane.
@en
The inhibitory effect of ErbB2 ...... plexes at the plasma membrane.
@nl
prefLabel
The inhibitory effect of ErbB2 ...... plexes at the plasma membrane.
@en
The inhibitory effect of ErbB2 ...... plexes at the plasma membrane.
@nl
P2093
P2860
P356
P1476
The inhibitory effect of ErbB2 ...... plexes at the plasma membrane.
@en
P2093
Camilla Haslekås
Espen Stang
Inger Helene Madshus
Kamilla Breen
Ketil W Pedersen
Lene E Johannessen
P2860
P304
P356
10.1091/MBC.E05-05-0456
P577
2005-10-05T00:00:00Z